What changed in BridgeBio Pharma, Inc.'s latest annual report
In the year ended 31 Dec 2025, BridgeBio Pharma, Inc.'s revenue rose 126.3% to USD 502.08m, from USD 221.90m; total liabilities rose 26.7% to USD 3.01bn, from USD 2.38bn; cash and cash equivalents fell 16.3% to USD 570.12m, from USD 681.10m.
Year ended 31 Dec 2025. Source: 10-K filed 24 Feb 2026, read it on SEC EDGAR.
USD 221.90m to USD 502.08m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 221.90m | 502.08m | Up 126.3% |
| Total assets | 919.34m | 936.02m | Up 1.8% |
| Total liabilities | 2.38bn | 3.01bn | Up 26.7% |
| Long-term debt | Not reported | 2.01bn | Not comparable |
| Cash and cash equivalents | 681.10m | 570.12m | Down 16.3% |
| Shareholders' equity | -1.47bn | -2.09bn | Not comparable |
Questions people ask
Did BridgeBio Pharma, Inc.'s revenue grow last year?
Revenue grew 126.3%, from USD 221.90m to USD 502.08m in the year ended 31 Dec 2025.
How much cash and debt does BridgeBio Pharma, Inc. have?
At its latest year end (31 Dec 2025), BridgeBio Pharma, Inc. reported cash and cash equivalents of USD 570.12m and long-term debt of USD 2.01bn.
Where do these numbers come from?
From BridgeBio Pharma, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with BridgeBio Pharma, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%